ASCO Endorses EAU Guideline on Bladder Cancer

Share this content:
The American Society of Clinical Oncology endorsed the European Association of Urology’s guideline on bladder cancer.
The American Society of Clinical Oncology endorsed the European Association of Urology’s guideline on bladder cancer.

The American Society of Clinical Oncology (ASCO) endorsed the European Association of Urology's guideline on muscle-invasive bladder cancer (MIBC) and metastatic bladder cancer and has added qualifying statements, according to a statement published in the Journal of Clinical Oncology.1

Researchers from the ASCO Endorsement Panel led by Matthew Milowsky, MD, of the University of North Carolina Lineberger Comprehensive Cancer Center in Chapel Hill reviewed the guideline on MIBC and metastatic bladder cancer that was published online in March 2015 for developmental rigor.

They determined that the guideline was “clear, thorough, and based on the most relevant scientific evidence.”

In addition to its endorsement, the ASCO panel added qualifying statements that included highlighting the use of chemoradiotherapy for select patients with MIBC as well as recommending a preference for clinical trials in the treatment of metastatic disease in the second-line setting.

“The standard treatment of MIBC is neoadjuvant cisplatin-based combination chemotherapy followed by radical cystectomy,” the authors concluded. They recommended radical cystectomy alone in cisplatin-ineligible patients, and adjuvant cisplatin-based chemotherapy to high-risk patients who have not received neoadjuvant therapy.

RELATED: ASCO Endorses European Bladder Cancer Guideline

Finally, chemoradiotherapy should be offered as an alternative to cystectomy in appropriately selected patients with MIBC and in some patients for whom cystectomy may not be an option. Metastatic disease should be treated with cisplatin-containing combination chemotherapy, carboplatin combination chemotherapy, or single agents among patients ineligible for cisplatin.

Reference

  1. Milowsky MI, Rumble RB, Booth CM, et al. Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology guideline): American Society of Clinical Oncology clinical practice guideline endorsement [published online ahead of print March 21, 2016]. J Clin Oncol. doi: 10.1200/JCO.2015.65.9797.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters